With the rising popularity of glucagon-like peptide-1 agents for treating obesity, many bariatric surgery programs across the ...

The FDA is evaluating supply and demand and monitoring for patient safety. Semaglutide is a medication that mimics the ...

While some GLP-1s are approved for patients age 12 and older, only a few telehealth companies will prescribe them to children ...

The annual meeting of the American College of Gastroenterology was held from Oct. 25 to 30 in Philadelphia and attracted ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...

A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...